Stocks TelegraphStocks Telegraph
Stock Ideas

ATXI Company Profile and Key Details

NASDAQ : ATXI

Avenue Therapeutics, Inc.

$1.24
0.0149+1.22%
At Close 4:00 PM
71.41
BESG ScoreESG Rating

ATXI Stock Price Chart

Stock Price Today

Avenue Therapeutics, Inc. (ATXI) stock surged +2.45%, trading at $1.25 on NASDAQ, up from the previous close of $1.22. The stock opened at $1.22, fluctuating between $1.22 and $1.26 in the recent session.

Stock Snapshot

1.2201
Prev. Close
1.22
Open
2.57M
Market Cap
2.05M
Number of Shares
1.22
Day Low
1.258
Day High
0.05
P/E Ratio
84.56%
Free Float in %
24.78
EPS (TTM)
0.06
Book Value
-0.37
Cash Flow per Share
27.89K
Volume

Stock Price History Chart

DateOpenHighLowCloseVolume
Feb 10, 20251.221.261.221.2527.79K
Feb 07, 20251.301.331.221.2295.06K
Feb 06, 20251.341.371.301.30109.27K
Feb 05, 20251.361.391.311.3496.55K
Feb 04, 20251.291.421.231.3682.99K
Feb 03, 20251.351.361.221.2989.69K
Jan 31, 20251.311.411.261.36102.23K
Jan 30, 20251.301.361.261.32178.6K
Jan 29, 20251.371.431.301.34122.94K
Jan 28, 20251.331.401.261.39284.84K
Jan 27, 20251.591.631.411.50406.3K
Jan 24, 20252.052.061.681.8919.78M
Jan 23, 20251.731.941.731.8462.9K
Jan 22, 20251.851.881.601.7358.71K
Jan 21, 20251.891.921.781.85220.93K
Jan 17, 20251.921.921.791.8543.23K
Jan 16, 20251.901.901.721.7570.43K
Jan 15, 20251.891.941.811.9010.81K
Jan 14, 20251.901.961.821.8831.8K
Jan 13, 20251.802.041.661.90357K

Contact Details

New York, NY 10036

United States

Website: https://www.avenuetx.comContact: 781 652 4500

About Company

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.

Company Information

Employees3
Beta-0.18
Sales or Revenue$0.00
5Y Sales Change%0%
Fiscal Year EndsDecember
SectorHealthcare
IndustryBiotechnology

Frequently Asked Questions

What is the current Avenue Therapeutics, Inc. (ATXI) stock price?

Avenue Therapeutics, Inc. (NASDAQ: ATXI) stock price is $1.25 in the last trading session. During the trading session, ATXI stock reached the peak price of $1.26 while $1.22 was the lowest point it dropped to. The percentage change in ATXI stock occurred in the recent session was 2.45% while the dollar amount for the price change in ATXI stock was $0.03.

ATXI's industry and sector of operation?

The NASDAQ listed ATXI is part of Biotechnology industry that operates in the broader Healthcare sector. Avenue Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ATXI?

Dr. Xiaoqin Lu M.D.
Consultant
Dr. Alexandra MacLean M.D.
Chief Executive Officer & Director
Dr. Scott A. Reines M.D., Ph.D.
Interim Chief Medical Officer
Srinivas Subramanian
Executive Vice President
Mr. Srinivas Subramanian
Executive Vice President of Advanced Technology Solutions

How ATXI did perform over past 52-week?

ATXI's closing price is 1.23% higher than its 52-week low of $1.22 where as its distance from 52-week high of $15.00 is -91.77%.

How many employees does ATXI have?

Number of ATXI employees currently stands at 3.

Link for ATXI official website?

Official Website of ATXI is: https://www.avenuetx.com

How do I contact ATXI?

ATXI could be contacted at phone 781 652 4500 and can also be accessed through its website. ATXI operates from 1140 Avenue of the America, New York, NY 10036, United States.

How many shares of ATXI are traded daily?

ATXI stock volume for the day was 27.89K shares. The average number of ATXI shares traded daily for last 3 months was 393.99K.

What is the market cap of ATXI currently?

The market value of ATXI currently stands at $2.57M with its latest stock price at $1.25 and 2.05M of its shares outstanding.

logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph